QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:CGEM

Cullinan Oncology - CGEM Stock Forecast, Price & News

$11.91
+0.33 (+2.85%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.51
▼
$11.92
50-Day Range
$9.72
▼
$13.41
52-Week Range
$7.30
▼
$15.89
Volume
395,840 shs
Average Volume
152,229 shs
Market Capitalization
$543.22 million
P/E Ratio
5.36
Dividend Yield
N/A
Price Target
$50.00

Cullinan Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.8% Upside
$50.00 Price Target
Short Interest
Bearish
7.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Cullinan Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$53,200 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.64) to ($2.79) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

651st out of 1,030 stocks

Biological Products, Except Diagnostic Industry

98th out of 169 stocks

See Top Rated MarketRank™ Stocks Here

CGEM stock logo

About Cullinan Oncology (NASDAQ:CGEM) Stock

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGEM Stock News Headlines

February 2, 2023 | finance.yahoo.com
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
January 27, 2023 | americanbankingnews.com
Comparing X4 Pharmaceuticals (NASDAQ:XFOR) and Cullinan Oncology (NASDAQ:CGEM)
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 25, 2023 | seekingalpha.com
CGEM Cullinan Oncology, Inc.
January 24, 2023 | finance.yahoo.com
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
November 14, 2022 | finance.yahoo.com
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 2, 2022 | finance.yahoo.com
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
October 25, 2022 | finance.yahoo.com
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
February 2, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
September 4, 2022 | reuters.com
Cullinan Oncology Inc
August 16, 2022 | finance.yahoo.com
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 13, 2022 | seekingalpha.com
Cullinan Oncology (CGEM) Investor Presentation - Slideshow
August 10, 2022 | finance.yahoo.com
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 1, 2022 | finance.yahoo.com
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
July 5, 2022 | finance.yahoo.com
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
June 6, 2022 | seekingalpha.com
Cullinan Oncology discloses $8.3M share buy by insider
June 2, 2022 | seekingalpha.com
Cullinan Oncology grants stock options to employees
May 31, 2022 | finance.yahoo.com
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
May 19, 2022 | finance.yahoo.com
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 | benzinga.com
Short Volatility Alert: Cullinan Oncology
May 16, 2022 | investing.com
Cullinan Oncology Reports Q1 Net Loss of $12.9M
May 13, 2022 | nasdaq.com
Notable Thursday Option Activity: ROKU, CGEM, CPRI
May 12, 2022 | finance.yahoo.com
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 8, 2022 | finance.yahoo.com
Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
April 27, 2022 | finance.yahoo.com
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
April 5, 2022 | finance.yahoo.com
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
April 4, 2022 | finance.yahoo.com
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See More Headlines
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGEM Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGEM
CUSIP
N/A
CIK
1789972
Web
www.cullinanoncology.com
Phone
617-410-4650
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+319.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.22
Trailing P/E Ratio
5.36
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,570,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.66%
Return on Assets
-31.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.47
Quick Ratio
21.47

Sales & Book Value

Annual Sales
$18.94 million
Price / Sales
28.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.74 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
45,610,000
Free Float
42,191,000
Market Cap
$543.22 million
Optionable
Not Optionable
Beta
0.13

Key Executives

  • Mr. Nadim AhmedMr. Nadim Ahmed (Age 54)
    Pres, CEO & Director
    Comp: $824k
  • Mr. Jeffrey TrigilioMr. Jeffrey Trigilio (Age 37)
    CFO & Treasurer
    Comp: $634.5k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $702.8k
  • Ms. Jacquelyn L. Sumer J.D. (Age 44)
    Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
  • Ms. Rose Weldon
    VP of Communications
  • Mr. Steve Andre
    Chief HR Officer
  • Dr. Corinne Savill Ph.D. (Age 63)
    Chief Bus. Officer
  • Dr. Jennifer Michaelson Ph.D.Dr. Jennifer Michaelson Ph.D. (Age 54)
    Chief Devel. Officer
  • Ms. Kerry Whalen
    Sr. Director of Preclinical & Early Devel.
  • Dr. Jeffrey Jones M.B.A. (Age 51)
    M.D., M.P.H., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CGEM Stock - Frequently Asked Questions

Should I buy or sell Cullinan Oncology stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings or view top-rated stocks.

What is Cullinan Oncology's stock price forecast for 2023?

3 brokers have issued 12 month target prices for Cullinan Oncology's stock. Their CGEM share price forecasts range from $50.00 to $50.00. On average, they predict the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 319.8% from the stock's current price.
View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts.

How have CGEM shares performed in 2023?

Cullinan Oncology's stock was trading at $10.55 at the beginning of the year. Since then, CGEM stock has increased by 12.9% and is now trading at $11.91.
View the best growth stocks for 2023 here.

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our CGEM earnings forecast.

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) released its earnings results on Monday, November, 14th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.43.

When did Cullinan Oncology IPO?

(CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Cullinan Oncology's stock symbol?

Cullinan Oncology trades on the NASDAQ under the ticker symbol "CGEM."

Who are Cullinan Oncology's major shareholders?

Cullinan Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.18%), Nisa Investment Advisors LLC (0.03%), SG Americas Securities LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2.
View institutional ownership trends.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cullinan Oncology's stock price today?

One share of CGEM stock can currently be purchased for approximately $11.91.

How much money does Cullinan Oncology make?

Cullinan Oncology (NASDAQ:CGEM) has a market capitalization of $543.22 million and generates $18.94 million in revenue each year. The company earns $-65,570,000.00 in net income (profit) each year or $2.22 on an earnings per share basis.

How can I contact Cullinan Oncology?

The official website for the company is www.cullinanoncology.com. The company can be reached via phone at 617-410-4650 or via email at investors@cullinanoncology.com.

This page (NASDAQ:CGEM) was last updated on 2/2/2023 by MarketBeat.com Staff